Send to

Choose Destination
See comment in PubMed Commons below
Med Oncol. 2010 Jun;27(2):430-3. doi: 10.1007/s12032-009-9228-6. Epub 2009 May 12.

Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study.

Author information

  • 1Department of Oncology, Division of Cellular and Molecular Medicine, St George's University of London, 2nd Floor, Jenner Wing, London SW17 0RE, UK.


The proportion of people surviving pancreatic cancer is extremely low, with just 10% of patients diagnosed with any stage of the disease living beyond 1 year and a 5-year relative survival rate of <5%. The lack of effective therapy is one the main reason for such a bleak outlook. Herein, we report on a patient with pancreatic adenocarcinoma and metastatic disease treated with a combination regimen of gemcitabine and lenalidomide, without major complications. We also present in vitro data that highlight a hyper-additive effect of the two drugs when used in combination. To date, 33 months after diagnosis, the patient remains well and continues in full-time employment.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center